Skip to main content

Table 1 Clinicopathologic features of patients on active surveillance at diagnosis

From: Impact of bilateral biopsy-detected prostate cancer on an active surveillance population

Variables

n (%)

Median (IQR)

Follow-up (m)

130

42.5 (24–74)

Age (years)

130

61 (57–66)

 < 50 y

5 (4)

48

 50–60 y

56 (43)

57

 > 60 y

69 (53)

66

PSA (ng/ml)

130

5.08 (4.2–7)

 < 4 ng/ml

26 (20)

3.2 l

 ≥ 4 ng/ml

104 (80)

5.9

PSA density

130

0.13 (0.09–0.16)

 ≤ 0.15

112 (86)

0.12

BMI (kg/m2)

130

27.5 (25.6–31.7)

 ≤ 30

89 (68.5)

26.2

 > 30

41 (31.5)

32.8

Prostate Volume (cc)

130

42 (32–57)

 < 30

23 (17.7)

24

 30–60

82 (63.1)

42

 > 60

25 (19.2)

73

Follow-up biopsies

130

2.5 (2–4)

 2

65 (50)

2

 3

29 (22.3)

3

  > 4

36 (27.7)

4.5

Max Core Involvement %a

130

5 (3–10)

  1. aMaximal Percentage of the most involved core
  2. Prostate Specific Antigen (PSA), Body Max Index (BMI)